Strongbridge Secures Third US Patent for Recorlev

Strongbridge Secures Third US Patent for Recorlev

296248

Strongbridge Secures Third US Patent for Recorlev

The U.S. Patent and Trademark Office has issued a new patent to Strongbridge Biopharma that covers a method of using Recorlev (levoketoconazole), the company’s investigational treatment for endogenous Cushing’s syndrome, to treat people with Cushing’s who also are taking metformin for type 2 diabetes. According to a company press release, the new patent (No. 11,020,393)  “Methods of Treating Disease with Levoketoconazole,” will expire March 2, 2040. This is the third U.S. patent related to Recorlev that…

You must be logged in to read/download the full post.